Adequate hemodynamic management using well-defi ned perioperative goal-directed therapy (GDT) is a cornerstone of tissue perfusion and oxygenation that can improve outcome. Th e aim of GDT is to prevent tissue oxygen debt and energy crisis by maintaining adequate tissue perfusion and oxygenation in relation to increased metabolic demand during major surgery.
Adequate hemodynamic management using well-defi ned perioperative goal-directed therapy (GDT) is a cornerstone of tissue perfusion and oxygenation that can improve outcome. Th e aim of GDT is to prevent tissue oxygen debt and energy crisis by maintaining adequate tissue perfusion and oxygenation in relation to increased metabolic demand during major surgery.
In an elegant study in the previous issue of Critical Care, Jhanji and colleagues [1] highlighted the important pathophysiological mechanisms involved behind the benefi t of GDT. Th e authors showed that stroke volumetargeted colloid administration coupled with a fi xed infusion rate of dopexamine improved oxygen delivery (DO 2 ), central venous oxygen saturation (ScvO 2 ), microvascular blood fl ow, and tissue oxygenation and that fl uid therapy alone led to additional modest improvements. Th ese data echo previous fi ndings that optimizing DO 2 improves outcome [2] [3] [4] [5] and that microvascular fl ow abnormalities could be a key point in determining postoperative complications following high-risk surgery [6] . Th ese results were consistent with those of Lobo and colleagues [5] , who compared the use of fl uids and dobutamine and fl uids alone in high-risk surgical patients. Th e use of fl uids and dobutamine to achieve a DO 2 goal (of greater than 600 mL/min per m 2 ) determined better postoperative outcomes than fl uids alone did.
Th e study of Jhanji and colleagues, however, raises several important questions that might deserve future clinical trials. First, we have to ask whether the hemodynamic optimization should be performed postoperatively or, more logically, once the surgical trauma is induced. In the three study groups, it is clear that baseline postoperative infl ammatory markers were largely elevated, rendering the hemodynamic optimiza tion less able to reduce complications that appear to be present at a very high rate regardless of the intervention protocol (between 58% and 69% of the patients). Indeed, several pieces of evidence suggest that the timing of therapeutic intervention during GDT could be a critical issue [7] , and most studies predominantly performed GDT starting intraoperatively [8] . Second, one may question the use of a fi xed low infusion rate of dopexa mine (0.5 μg/kg per minute) without targeting any specifi c goals for cardiac output or DO 2 . Although the use of a low dose of dopexamine demonstrated benefi ts in terms of survival and reduction in hospital stay in a previous small-scale study [9] , this was not observed here by Jhanji and colleagues [1] in this randomized trial on a larger scale. In the latter context, it seems important to emphasize that the serum lactate concentration and the base defi cit remained a bit higher (though not signifi cantly so) during the fi rst 4 hours of treatment in the fi xed-dose dopexamine treatment group. Th erefore, two important complementary questions remain: Do we need, as for fl uids, an individualized approach to deliver inotrope during GDT? What should be the goal to address the Abstract There is substantial evidence to demonstrate the benefi ts of goal-directed hemodynamic optimization using fl uid loading or inotropic support or both to improve outcome during major surgery. However, until now, only limited pathophysiological data have been available to explain this benefi t. The maintenance of adequate tissue perfusion and global oxygen delivery is an essential goal for therapy. In an interesting study, Jhanji and colleagues provided additional data that emphasize the roles of optimization of intravascular fl uid status and low doses of inotropes to improve microvascular blood fl ow and tissue oxygenation. This commentary aims to highlight some issues raised by this important study and provides additional elements to further position these results.
adequacy of inotrope infusion? From an 'energy debt' perspective, it is certainly much more important to consider the DO 2 -to-O 2 consumption (VO 2 ) relationship than to indicate a specifi c value of DO 2 as a goal [10] . To this end, Donati and colleagues [7] demonstrated improved outcome in patients treated with individualized GDT using fl uids and dobutamine titrated to maintain O 2 extraction (ERO 2 , the ratio of VO 2 to DO 2 ) at less than 27% (corresponding approximately to an ScvO 2 of greater than 73%). An increase in VO 2 without a corresponding increase in DO 2 , or a decrease in DO 2 and no change in O 2 requirements, results in an increase in ERO 2 , rendering ScvO 2 an interesting contributor to patient monitoring. In critical illness, however, the ability of tissue to increase ERO 2 might be impaired, and 'normalized ScvO 2 ' would lose its ability to guide fl uid or inotrope therapy [11, 12] . Th is constitutes the third impor tant remaining issue raised by this study: Should we systematically integrate other markers of cellular energy adequacy (besides ScvO 2 ) such as serum lactate [12, 13] , base defi cit, or tissue hypercarbia [14] ? In any case, these markers deserve further investigations in GDT-based protocols, as has been done in critical illness such as severe sepsis [12, 15] , before being considered eligible tools for high-risk surgery.
In total, we believe it would be more rational to apply GDT according to individual patients' targets based on their specifi c physiological profi le, whether it pertains to fl uid loading or dopexamine titration. It is obvious that the use of inotropes should be cautious in patients with high risk of ischemic cardiovascular events, in which beta stimulation may be harmful. In a previous study of 122 high-risk patients (81% with an American Society of Anesthesiologists score of at least 3), Pearse and colleagues [16] reported a 13% rate of adverse events (tachycardia and myocardial ischemia) using mean doses of dopexamine of 0.75 μg/kg per minute (interquartile range of 0.5 to 1.0 μg/kg per minute) whereas 24% of patients did not achieve the DO 2 goal despite receiving the maximum therapy allowed. Inotrope titration should integrate the relationship of O 2 needs to the O 2 costs to be delivered. Finally, we feel that GDT must be applied at the time of injury (that is, intraoperatively) and not after infl ammation has already started. Such an approach, applied in further clinical trials, might provide us with responses to our yet unanswered questions.
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